An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome

C. J. Harrison, Anthony Moorman, C. Schwab, A. J. Carroll, E. A. Raetz, M. Devidas, S. Strehl, K. Nebral, J. Harbott, A. Teigler-Schlegel, M. Zimmerman, N. Dastuge, A. Baruchel, J. Soulier, M. F. Auclerc, A. Attarbaschi, G. Mann, B. Stark, G. Cazzaniga, L. ChiltonP. Vandenberghe, E. Forestier, I. Haltrich, S. C. Raimondi, M. Parihar, J. P. Bourquin, J. Tchinda, C. Haferlach, A. Vora, S. P. Hunger, N. A. Heerema, O. A. Haas

Research output: Contribution to journalArticle

Abstract

Intrachromosomal amplification of chromosome 21 (iAMP21) defines a distinct cytogenetic subgroup of childhood B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). To date, fluorescence in situ hybridisation (FISH), with probes specific for the RUNX1 gene, provides the only reliable detection method (five or more RUNX1 signals per cell). Patients with iAMP21 are older (median age 9 years) with a low white cell count. Previously, we demonstrated a high relapse risk when these patients were treated as standard risk. Recent studies have shown improved outcome on intensive therapy. In view of these treatment implications, accurate identification is essential. Here we have studied the cytogenetics and outcome of 530 iAMP21 patients that highlighted the association of specific secondary chromosomal and genetic changes with iAMP21 to assist in diagnosis, including the gain of chromosome X, loss or deletion of chromosome 7, ETV6 and RB1 deletions. These iAMP21 patients when treated as high risk showed the same improved outcome as those in trial-based studies regardless of the backbone chemotherapy regimen given. This study reinforces the importance of intensified treatment to reduce the risk of relapse in iAMP21 patients. This now well-defined patient subgroup should be recognised by World Health Organisation (WHO) as a distinct entity of BCP-ALL.

Original languageEnglish (US)
Pages (from-to)1015-1021
Number of pages7
JournalLeukemia
Volume28
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Chromosomes, Human, Pair 21
Cytogenetics
B-Lymphoid Precursor Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Chromosomes, Human, Pair 7
X Chromosome
Fluorescence In Situ Hybridization
Therapeutics
Cell Count
Drug Therapy
Genes

Keywords

  • BCP-ALL
  • chromosomal abnormalities
  • genetics
  • iAMP21
  • outcome
  • poor prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

An international study of intrachromosomal amplification of chromosome 21 (iAMP21) : Cytogenetic characterization and outcome. / Harrison, C. J.; Moorman, Anthony; Schwab, C.; Carroll, A. J.; Raetz, E. A.; Devidas, M.; Strehl, S.; Nebral, K.; Harbott, J.; Teigler-Schlegel, A.; Zimmerman, M.; Dastuge, N.; Baruchel, A.; Soulier, J.; Auclerc, M. F.; Attarbaschi, A.; Mann, G.; Stark, B.; Cazzaniga, G.; Chilton, L.; Vandenberghe, P.; Forestier, E.; Haltrich, I.; Raimondi, S. C.; Parihar, M.; Bourquin, J. P.; Tchinda, J.; Haferlach, C.; Vora, A.; Hunger, S. P.; Heerema, N. A.; Haas, O. A.

In: Leukemia, Vol. 28, No. 5, 01.01.2014, p. 1015-1021.

Research output: Contribution to journalArticle

Harrison, CJ, Moorman, A, Schwab, C, Carroll, AJ, Raetz, EA, Devidas, M, Strehl, S, Nebral, K, Harbott, J, Teigler-Schlegel, A, Zimmerman, M, Dastuge, N, Baruchel, A, Soulier, J, Auclerc, MF, Attarbaschi, A, Mann, G, Stark, B, Cazzaniga, G, Chilton, L, Vandenberghe, P, Forestier, E, Haltrich, I, Raimondi, SC, Parihar, M, Bourquin, JP, Tchinda, J, Haferlach, C, Vora, A, Hunger, SP, Heerema, NA & Haas, OA 2014, 'An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome', Leukemia, vol. 28, no. 5, pp. 1015-1021. https://doi.org/10.1038/leu.2013.317
Harrison, C. J. ; Moorman, Anthony ; Schwab, C. ; Carroll, A. J. ; Raetz, E. A. ; Devidas, M. ; Strehl, S. ; Nebral, K. ; Harbott, J. ; Teigler-Schlegel, A. ; Zimmerman, M. ; Dastuge, N. ; Baruchel, A. ; Soulier, J. ; Auclerc, M. F. ; Attarbaschi, A. ; Mann, G. ; Stark, B. ; Cazzaniga, G. ; Chilton, L. ; Vandenberghe, P. ; Forestier, E. ; Haltrich, I. ; Raimondi, S. C. ; Parihar, M. ; Bourquin, J. P. ; Tchinda, J. ; Haferlach, C. ; Vora, A. ; Hunger, S. P. ; Heerema, N. A. ; Haas, O. A. / An international study of intrachromosomal amplification of chromosome 21 (iAMP21) : Cytogenetic characterization and outcome. In: Leukemia. 2014 ; Vol. 28, No. 5. pp. 1015-1021.
@article{2dca4ec4b03644f38c93af77019a6be6,
title = "An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome",
abstract = "Intrachromosomal amplification of chromosome 21 (iAMP21) defines a distinct cytogenetic subgroup of childhood B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). To date, fluorescence in situ hybridisation (FISH), with probes specific for the RUNX1 gene, provides the only reliable detection method (five or more RUNX1 signals per cell). Patients with iAMP21 are older (median age 9 years) with a low white cell count. Previously, we demonstrated a high relapse risk when these patients were treated as standard risk. Recent studies have shown improved outcome on intensive therapy. In view of these treatment implications, accurate identification is essential. Here we have studied the cytogenetics and outcome of 530 iAMP21 patients that highlighted the association of specific secondary chromosomal and genetic changes with iAMP21 to assist in diagnosis, including the gain of chromosome X, loss or deletion of chromosome 7, ETV6 and RB1 deletions. These iAMP21 patients when treated as high risk showed the same improved outcome as those in trial-based studies regardless of the backbone chemotherapy regimen given. This study reinforces the importance of intensified treatment to reduce the risk of relapse in iAMP21 patients. This now well-defined patient subgroup should be recognised by World Health Organisation (WHO) as a distinct entity of BCP-ALL.",
keywords = "BCP-ALL, chromosomal abnormalities, genetics, iAMP21, outcome, poor prognosis",
author = "Harrison, {C. J.} and Anthony Moorman and C. Schwab and Carroll, {A. J.} and Raetz, {E. A.} and M. Devidas and S. Strehl and K. Nebral and J. Harbott and A. Teigler-Schlegel and M. Zimmerman and N. Dastuge and A. Baruchel and J. Soulier and Auclerc, {M. F.} and A. Attarbaschi and G. Mann and B. Stark and G. Cazzaniga and L. Chilton and P. Vandenberghe and E. Forestier and I. Haltrich and Raimondi, {S. C.} and M. Parihar and Bourquin, {J. P.} and J. Tchinda and C. Haferlach and A. Vora and Hunger, {S. P.} and Heerema, {N. A.} and Haas, {O. A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/leu.2013.317",
language = "English (US)",
volume = "28",
pages = "1015--1021",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - An international study of intrachromosomal amplification of chromosome 21 (iAMP21)

T2 - Cytogenetic characterization and outcome

AU - Harrison, C. J.

AU - Moorman, Anthony

AU - Schwab, C.

AU - Carroll, A. J.

AU - Raetz, E. A.

AU - Devidas, M.

AU - Strehl, S.

AU - Nebral, K.

AU - Harbott, J.

AU - Teigler-Schlegel, A.

AU - Zimmerman, M.

AU - Dastuge, N.

AU - Baruchel, A.

AU - Soulier, J.

AU - Auclerc, M. F.

AU - Attarbaschi, A.

AU - Mann, G.

AU - Stark, B.

AU - Cazzaniga, G.

AU - Chilton, L.

AU - Vandenberghe, P.

AU - Forestier, E.

AU - Haltrich, I.

AU - Raimondi, S. C.

AU - Parihar, M.

AU - Bourquin, J. P.

AU - Tchinda, J.

AU - Haferlach, C.

AU - Vora, A.

AU - Hunger, S. P.

AU - Heerema, N. A.

AU - Haas, O. A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Intrachromosomal amplification of chromosome 21 (iAMP21) defines a distinct cytogenetic subgroup of childhood B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). To date, fluorescence in situ hybridisation (FISH), with probes specific for the RUNX1 gene, provides the only reliable detection method (five or more RUNX1 signals per cell). Patients with iAMP21 are older (median age 9 years) with a low white cell count. Previously, we demonstrated a high relapse risk when these patients were treated as standard risk. Recent studies have shown improved outcome on intensive therapy. In view of these treatment implications, accurate identification is essential. Here we have studied the cytogenetics and outcome of 530 iAMP21 patients that highlighted the association of specific secondary chromosomal and genetic changes with iAMP21 to assist in diagnosis, including the gain of chromosome X, loss or deletion of chromosome 7, ETV6 and RB1 deletions. These iAMP21 patients when treated as high risk showed the same improved outcome as those in trial-based studies regardless of the backbone chemotherapy regimen given. This study reinforces the importance of intensified treatment to reduce the risk of relapse in iAMP21 patients. This now well-defined patient subgroup should be recognised by World Health Organisation (WHO) as a distinct entity of BCP-ALL.

AB - Intrachromosomal amplification of chromosome 21 (iAMP21) defines a distinct cytogenetic subgroup of childhood B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). To date, fluorescence in situ hybridisation (FISH), with probes specific for the RUNX1 gene, provides the only reliable detection method (five or more RUNX1 signals per cell). Patients with iAMP21 are older (median age 9 years) with a low white cell count. Previously, we demonstrated a high relapse risk when these patients were treated as standard risk. Recent studies have shown improved outcome on intensive therapy. In view of these treatment implications, accurate identification is essential. Here we have studied the cytogenetics and outcome of 530 iAMP21 patients that highlighted the association of specific secondary chromosomal and genetic changes with iAMP21 to assist in diagnosis, including the gain of chromosome X, loss or deletion of chromosome 7, ETV6 and RB1 deletions. These iAMP21 patients when treated as high risk showed the same improved outcome as those in trial-based studies regardless of the backbone chemotherapy regimen given. This study reinforces the importance of intensified treatment to reduce the risk of relapse in iAMP21 patients. This now well-defined patient subgroup should be recognised by World Health Organisation (WHO) as a distinct entity of BCP-ALL.

KW - BCP-ALL

KW - chromosomal abnormalities

KW - genetics

KW - iAMP21

KW - outcome

KW - poor prognosis

UR - http://www.scopus.com/inward/record.url?scp=84899979360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899979360&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.317

DO - 10.1038/leu.2013.317

M3 - Article

C2 - 24166298

AN - SCOPUS:84899979360

VL - 28

SP - 1015

EP - 1021

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -